Evidence map›Paper›PMID 41230651›Full record

Trial reportFuture oncology (London, England)2025

BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line

Scott Kopetz, Josep Tabernero, Elena Élez

Abstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Scott KopetzDepartment of Gastrointestinal Medical Oncology,University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9647-3416
Josep TaberneroMedical Oncology Department, Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0002-2495-8139
Elena ÉlezMedical Oncology Department, Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0002-4653-6324

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The BREAKWATER Phase III study investigated encorafenib and cetuximab plus mFOLFOX6 versus chemotherapy with or without bevacizumab for the treatment of patients with previously untreated

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsProto-Oncogene Proteins B-rafAgedCarbamatesCetuximabClinical Trials, Phase III as TopicFemaleFluorouracilHumansLeucovorinMaleMiddle AgedMutationNeoplasm MetastasisOrganoplatinum CompoundsBRAF protein, humanCarbamatesCetuximabencorafenibFluorouracilLeucovorinOrganoplatinum CompoundsProto-Oncogene Proteins B-rafSulfonamidesBRAF-mutantEncorafenibFirst-lineMetastatic colorectal cancer

Identifiers

PMID41230651
PMCPMC12698039

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.